JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tran, A.
Right arrow Articles by Silverman, D. H.S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tran, A.
Right arrow Articles by Silverman, D. H.S.
Journal of Nuclear Medicine Vol. 46 No. 9 1455-1459
© 2005 by Society of Nuclear Medicine


Clinical Investigations

18F-FDG PET for Staging Breast Cancer in Patients with Inner-Quadrant Versus Outer-Quadrant Tumors: Comparison with Long-Term Clinical Outcome

Amy Tran, BS, Betty S. Pio, MS, Bahareh Khatibi, BS, Johannes Czernin, MD, Michael E. Phelps, PhD and Daniel H.S. Silverman, MD, PhD

Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California

Extraaxillary metastases (i.e., in the absence of axillary involvement) are more likely to develop in patients with inner-quadrant (IQ) breast cancer than in patients with outer-quadrant (OQ) primary tumors. The relative difficulty of identifying extraaxillary metastases may lead to understaging of cancer in these patients. This study examined whether 18F-FDG PET findings were differentially associated with the location of primary tumors, and with long-term prognosis, in IQ and OQ patients. Methods: Follow-up data were obtained for 141 patients whose breast cancer was staged by PET and who were documented to have IQ (n = 42) or OQ (n = 99) primaries. Results were stratified according to PET findings consistent with different metastatic patterns. Data were further analyzed with respect to disease outcome after a mean 3-y follow-up period. Results: Among IQ patients, progressive disease was identified in 26.1%, compared with 13.1% of OQ patients, for a relative risk (RR) of 2.0. Of patients with PET findings of isolated extraaxillary metastases, 36.1% had progressive disease, compared with 10.7% of other patients (RR = 3.4), and 61.9% of IQ patients had isolated extraaxillary metastases identified on PET, compared with 10.1% of OQ patients (RR = 6.1). Conclusion: IQ patients demonstrated a 6-fold greater frequency of PET findings of isolated extraaxillary metastasis, and such findings were associated with triple the risk for disease progression. Patients with IQ tumors could be vulnerable to understaging with conventional staging approaches and may particularly benefit from PET during the staging process.

Key Words: breast cancer • PET • FDG


Related articles in JNM:

THIS MONTH IN JNM

JNM 2005 46: 8a-9a. [Full Text]  



This article has been cited by other articles:


Home page
JCOHome page
S. Chia, S. M. Swain, D. R. Byrd, and D. A. Mankoff
Locally Advanced and Inflammatory Breast Cancer
J. Clin. Oncol., February 10, 2008; 26(5): 786 - 790.
[Full Text] [PDF]


Home page
RadioGraphicsHome page
E. L. Rosen, W. B. Eubank, and D. A. Mankoff
FDG PET, PET/CT, and Breast Cancer Imaging
RadioGraphics, October 1, 2007; 27(suppl_1): S215 - S229.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2005 by the Society of Nuclear Medicine.